QUOTED. David Stein.
Babson Diagnostics recently raised $31m to accelerate commercialization of its blood testing “ecosystem.” CEO David Stein discussed the potential of the technology.
“There’s always been this holy grail of diagnostics. Could you perform very large test panels from very small volumes of blood?” – David Stein, CEO, Babson Diagnostics
- Find out more: Babson Diagnostics Plans To Deliver What Theranos Could Not
Click here for a free trial of Medtech Insight